uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Genetics and Pathology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Clinical Chemistry)
Show others and affiliations
1998 (English)In: Gut, ISSN 0017-5749, E-ISSN 1468-3288, Vol. 43, no 2, 223-228 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Type 1 gastric carcinoids are associated with hypergastrinaemia and chronic atrophic gastritis, type 2 occur in patients with multiple endocrine neoplasia type 1 combined with Zollinger-Ellison syndrome, and type 3 lack any relation to hypergastrinaemia. Type 1 tumours are usually benign whereas type 3 are highly malignant. AIMS: To identify possible tumour markers in patients with gastric carcinoids. PATIENTS/METHOD: Nine patients with type 1, one with type 2, and five with type 3 were evaluated with regard to symptoms, hormone profile, and prognosis. RESULTS: Plasma chromogranin A was increased in all patients but was higher (p < 0.01) in those with type 3 than those with type 1 carcinoids. All patients with type 3 carcinoids died from metastatic disease, but none of the type 1 patients died as a result of their tumours. One type 1 patient with a solitary liver metastasis received interferon alpha and octreotide treatment. Nine months later, the metastasis was no longer detectable. She is still alive eight years after diagnosis, without recurrent disease. This represents the only reported case of foregut carcinoid with an unresectable liver metastasis that seems to be have been cured by biotherapy. CONCLUSIONS: Plasma chromogranin A appears to be a valuable tumour marker for all types of gastric carcinoid. Combination therapy with interferon alpha and octreotide may be beneficial in patients with metastasising type 1 gastric carcinoids.

Place, publisher, year, edition, pages
1998. Vol. 43, no 2, 223-228 p.
Keyword [en]
gastric carcinoids, chromogranin, histamine, interferon, octreotide
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-55620PubMedID: 10189848OAI: oai:DiVA.org:uu-55620DiVA: diva2:83528
Available from: 2008-04-20 Created: 2008-04-20 Last updated: 2017-12-04Bibliographically approved

Open Access in DiVA

No full text

PubMed

Authority records BETA

Granberg, DanWilander, ErikStridsberg, MatsSkogseid, BrittÖberg, Kjell

Search in DiVA

By author/editor
Granberg, DanWilander, ErikStridsberg, MatsSkogseid, BrittÖberg, Kjell
By organisation
Department of Medical SciencesDepartment of Genetics and Pathology
In the same journal
Gut
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 374 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf